Equities research analysts expect that Viewray Inc (NASDAQ:VRAY) will post ($0.26) earnings per share for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Viewray’s earnings, with estimates ranging from ($0.32) to ($0.18). Viewray posted earnings per share of ($0.17) in the same quarter last year, which would suggest a negative year-over-year growth rate of 52.9%. The company is scheduled to announce its next quarterly earnings report on Thursday, March 12th.
On average, analysts expect that Viewray will report full year earnings of ($1.13) per share for the current fiscal year, with EPS estimates ranging from ($1.20) to ($1.05). For the next year, analysts expect that the firm will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.16) to ($0.65). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Viewray.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.06. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $20.66 million. Viewray had a negative return on equity of 75.41% and a negative net margin of 110.61%. The firm’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.39) earnings per share.
A number of research analysts have issued reports on the stock. Mizuho restated a “buy” rating and set a $9.00 target price on shares of Viewray in a research report on Tuesday. ValuEngine cut shares of Viewray from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Jefferies Financial Group dropped their price target on shares of Viewray from $14.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, August 9th. BidaskClub raised shares of Viewray from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Piper Jaffray Companies set a $6.00 target price on shares of Viewray and gave the stock a “buy” rating in a report on Tuesday, October 15th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $7.30.
Several large investors have recently made changes to their positions in VRAY. Park West Asset Management LLC grew its holdings in Viewray by 87.3% during the second quarter. Park West Asset Management LLC now owns 7,615,325 shares of the company’s stock valued at $67,091,000 after purchasing an additional 3,549,255 shares during the period. Perceptive Advisors LLC lifted its holdings in shares of Viewray by 13.5% during the 2nd quarter. Perceptive Advisors LLC now owns 5,455,243 shares of the company’s stock valued at $48,061,000 after purchasing an additional 649,593 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Viewray by 1.5% during the 2nd quarter. BlackRock Inc. now owns 4,894,543 shares of the company’s stock valued at $43,121,000 after purchasing an additional 72,529 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Viewray by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,673,074 shares of the company’s stock valued at $32,359,000 after purchasing an additional 75,466 shares during the period. Finally, Bamco Inc. NY grew its position in shares of Viewray by 18.3% in the 2nd quarter. Bamco Inc. NY now owns 1,875,809 shares of the company’s stock valued at $16,526,000 after purchasing an additional 290,000 shares during the period.
Shares of VRAY stock opened at $3.40 on Friday. The firm has a market cap of $329.54 million, a price-to-earnings ratio of -3.47 and a beta of 1.09. Viewray has a 12 month low of $2.12 and a 12 month high of $9.76. The company has a quick ratio of 2.58, a current ratio of 3.70 and a debt-to-equity ratio of 0.62. The stock has a 50-day moving average price of $2.79 and a 200 day moving average price of $5.57.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
See Also: How does quantitative easing work?
Get a free copy of the Zacks research report on Viewray (VRAY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.